Woodline Partners LP Acquires 18,072 Shares of Hologic, Inc. (NASDAQ:HOLX)

Woodline Partners LP raised its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 14.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 144,072 shares of the medical equipment provider's stock after purchasing an additional 18,072 shares during the period. Woodline Partners LP owned 0.06% of Hologic worth $10,386,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Venturi Wealth Management LLC lifted its holdings in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 260 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares during the last quarter. Smithfield Trust Co lifted its holdings in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new stake in shares of Hologic during the 4th quarter worth $49,000. 94.73% of the stock is owned by institutional investors.

Insider Activity at Hologic

In other Hologic news, Director Martin D. Madaus acquired 5,445 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director now directly owns 5,445 shares of the company's stock, valued at approximately $300,781.80. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.88% of the stock is owned by corporate insiders.

Hologic Trading Up 2.6%

Shares of HOLX stock traded up $1.62 during mid-day trading on Wednesday, reaching $63.79. The stock had a trading volume of 2,962,205 shares, compared to its average volume of 3,060,706. The stock's 50-day moving average price is $58.05 and its two-hundred day moving average price is $66.23. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The firm has a market capitalization of $14.22 billion, a PE ratio of 20.11, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the previous year, the company earned $1.03 earnings per share. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. Equities analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of research analyst reports. William Blair reaffirmed an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Raymond James reaffirmed an "outperform" rating and set a $71.00 price objective (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Stephens lowered their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, Royal Bank of Canada lowered their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Twelve investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Hologic presently has a consensus rating of "Hold" and an average target price of $77.42.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.